Patents by Inventor Bernard Fanget

Bernard Fanget has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190185548
    Abstract: The present invention relates to polyclonal antibodies for use in the prevention and/or treatment of the Ebola virus disease. In one embodiment, the polyclonal antibodies are specific for a truncated Ebola virus GP glycoprotein. Said polyclonal antibodies are preferably non-human antibodies and are provided in a serum free pharmaceutical composition. The present invention also relates to a method of prevention and/or treatment of Ebola virus disease in a subject in need thereof, comprising administering to said subject polyclonal antibodies specific for the Ebola virus.
    Type: Application
    Filed: June 6, 2017
    Publication date: June 20, 2019
    Inventors: Sandrine CRABE, Jerome DENIS, Bernard FANGET
  • Publication number: 20180207288
    Abstract: An immunogenic product including IFN? coupled to a carrier protein molecule is capable to induce in vivo anti-IFN? antibodies and is useful in treating IFN? related conditions.
    Type: Application
    Filed: March 26, 2018
    Publication date: July 26, 2018
    Inventors: Geraldine GROUARD-VOGEL, Olivier DHELLIN, Bernard FANGET, Pierre VANDEPAPELIERE, Camille ROUCAIROL
  • Patent number: 9993565
    Abstract: An immunogenic product including IFN? coupled to a carrier protein molecule is capable to induce in vivo anti-IFN? antibodies and is useful in treating IFN? related conditions.
    Type: Grant
    Filed: April 4, 2012
    Date of Patent: June 12, 2018
    Assignee: NEOVACS
    Inventors: Geraldine Grouard-Vogel, Olivier Dhellin, Bernard Fanget, Pierre Vandepapeliere, Camille Roucairol
  • Publication number: 20140023617
    Abstract: An immunogenic product including IFN? coupled to a carrier protein molecule is capable to induce in vivo anti-IFN? antibodies and is useful in treating IFN? related conditions.
    Type: Application
    Filed: April 4, 2012
    Publication date: January 23, 2014
    Applicant: NEOVACS
    Inventors: Geraldine Grouard-Vogel, Olivier Dhellin, Bernard Fanget, Pierre Vandepapeliere, Camille Roucairol
  • Publication number: 20120148526
    Abstract: An immunogenic product includes TNF? coupled with KLH, wherein the TNF? is strongly inactivated, which means that the product shows less than 30% of cytolytic activity and/or an inactivation factor of more than 15000, in the conditions of TEST A. An emulsion and a vaccine including the immunogenic product and methods for preparing the immunogenic product are also described.
    Type: Application
    Filed: December 8, 2010
    Publication date: June 14, 2012
    Applicant: NEOVACS
    Inventors: Géraldine GROUARD-VOGEL, Olivier DHELLIN, Bernard FANGET, Pierre VANDEPAPELIÈRE
  • Patent number: 6231860
    Abstract: Stabilizers for live vaccines and attenuated mono- or multivalent live vaccines, stabilized vaccines containig such stabilizers, and methods for preparing such vaccines, are disclosed. Said stabilizers for vaccines containing one or more attenuated live viruses include one or more components selected from each of the following groups: amino acids, disaccharides, polyalcohols and buffer solutions, with the proviso that one component selected from the disaccharide group is saccharose.
    Type: Grant
    Filed: September 21, 1998
    Date of Patent: May 15, 2001
    Assignee: Pasteur Merieux Serums & Vaccins
    Inventors: Bernard Fanget, Alain Francon
  • Patent number: 6149917
    Abstract: A method is disclosed for industrially producing a Japanese encephalitis vaccine, wherein (a) cells from a cell line are cultured, (b) the resulting cell culture is inoculated with a Japanese encephalitis virus in the presence of a viral growth medium, (c) the virus is propagated and multiplied on the cells, (d) the viral growth medium is recovered in the form of a suspension of viruses produced by the cells, (e) the virus suspension is purified in at least one ion exchange chromatography step and a gel permeation step, and (f) the virus suspension is formulated and converted into a pharmaceutical form to preserve it until the moment of use. A Japanese encephalitis vaccine characterised in that it comprises a Japanese encephalitis virus produced by culturing cells from a cell line, and in that the cellular DNA content is less than 100 pg/dose, is also disclosed.
    Type: Grant
    Filed: August 13, 1998
    Date of Patent: November 21, 2000
    Assignee: Pasteur Merieux Serums et Vaccins
    Inventors: Bernard Fanget, Alain Francon, Pierre Heimendinger
  • Patent number: 6008036
    Abstract: A method for purifying viruses from a cell line culture by chromatography, comprising an anion exchange chromatography step followed by a cation exchange chromatography step and optionally a metal-binding affinity chromatography step. The method is particularly suitable for producing viruses for use in vaccines.
    Type: Grant
    Filed: May 22, 1998
    Date of Patent: December 28, 1999
    Assignee: Pasteur Merieux Serums et Vaccins
    Inventors: Bernard Fanget, Alain Francon
  • Patent number: 5731187
    Abstract: Process for preparing hepatitis A (HAV) antigens and vaccines.The HAV virus is multiplied on competent cells, the infected cells are lysed, the supernatant is recovered and the purification is carried out by a chromatographic procedure on an anion-exchange support and a gel filtration procedure, the purification procedures being carried out in the presence of a detergent, and the chromatographic procedure being carried out under conditions which retain the virions or viral capsids, which are then eluted.
    Type: Grant
    Filed: October 13, 1993
    Date of Patent: March 24, 1998
    Assignee: Pasteur Merteux Serums Et Vaccins Societe Anonyme
    Inventors: Bernard Fanget, Alain Francon